ReviewInternational journal of molecular sciences2022
Biomarkers of Dementia with Lewy Bodies: Differential Diagnostic with Alzheimer's Disease.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Comparative analysis of white matter signal alterations in dementia with Lewy bodies and Alzheimer's disease: a systematic review and meta-analysis.Frontiers in radiology · 2025Pooled it
- Metabolic brain networks in dementia with Lewy bodies: from prodromal to manifest disease stages.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Fluid biomarkers for neurodegenerative diseases: a comprehensive update.Alzheimer's research & therapy · 2025Review
- Comparative Study on Multimodal Imaging Applications in Dementia with Lewy Bodies: From Imaging Features to Clinical Practice Implications.Brain sciences · 2025Article
- The Biomarker Profile of Alzheimer's Disease for Disease-Modifying Treatment Eligibility: Questions and Debates.International journal of molecular sciences · 2025Review
- The association between plasma and MRI biomarkers in dementia with lewy bodies.Alzheimer's research & therapy · 2025Article
- Altered glucose metabolism in default mode network and prefrontal circuit in patients with Kallmann syndrome.EJNMMI research · 2025Article
- Synapse vulnerability and resilience across the clinical spectrum of dementias.Nature reviews. Neurology · 2025Review
- Right anterior insula ASL hypoperfusion as a diagnostic biomarker of prodromal and mild dementia with Lewy bodies: preliminary evidence using a Bayesian approach.GeroScience · 2025Article
- Deep-learning based multi-modal models for brain age, cognition and amyloid pathology prediction.Alzheimer's research & therapy · 2025Article
- Cognitive impairment in Parkinson's disease and other parkinsonian syndromes.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Alice in Wonderland Syndrome in dementia with Lewy bodies: a case report exploring visual cognition dysfunction.Frontiers in neurology · 2025Article
- Dysfunctional default mode and visual networks underlie cognitive deficits in dementia with Lewy bodies: a resting-state fMRI study.Frontiers in aging neuroscience · 2025Article
- Protein Misfolding in the Pathogenesis and Diagnosis of Neurodegenerative Diseases (Review).Sovremennye tekhnologii v meditsine · 2025Review
- Research on magnetic resonance imaging in diagnosis of Alzheimer's disease.European journal of medical research · 2024Review
- Cerebrospinal Fluid Classical Biomarker Levels in Mixed vs. Pure ABiomedicines · 2024Article
- The Search for a Universal Treatment for Defined and Mixed Pathology Neurodegenerative Diseases.International journal of molecular sciences · 2024Review
- Article
- Substantia nigra hyperechogenicity and brain ventricular size as biomarkers of early dementia with Lewy bodies.Alzheimer's research & therapy · 2024Article
- Essential New Complexity-Based Themes for Patient-Centered Diagnosis and Treatment of Dementia and Predementia in Older People: Multimorbidity and Multilevel Phenomenology.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia with Lewy Bodies (DLB) is a common form of cognitive neurodegenerative disease. Only one third of patients are correctly diagnosed due to the clinical similarity mainly with Alzheimer's disease (AD). In this review, we evaluate the interest of different biomarkers: cerebrospinal fluid (CSF), brain MRI, FP-CIT SPECT, MIBG SPECT, PET by focusing more specifically on differential diagnosis between DLB and AD. FP-CIT SPECT is of high interest to discriminate DLB and AD, but not at the prodromal stage (i.e., MCI). MIBG SPECT with decreased cardiac sympathetic activity, perfusion SPECT with occipital hypoperfusion, FDG PET with occipital hypometabolism and cingulate island signs are of interest at the dementia stage but with a lower validity. Brain MRI has shown differences in group study with lower grey matter concentration of the Insula in prodromal DLB, but its interest in clinical routines is not demonstrated. Concerning CSF biomarkers, many studies have already examined the relevance of AD biomarkers but also alpha-synuclein assays in DLB, so we will focus as comprehensively as possible on other biomarkers (especially those that do not appear to be directly related to synucleinopathy) that may be of interest in the differential diagnosis between AD and DLB. Furthermore, we would like to highlight the growing interest in CSF synuclein RT-QuIC, which seems to be an excellent discrimination tool but its application in clinical routine remains to be demonstrated, given the non-automation of the process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.